RN517

RN517 is an investigational small interfering RNA (siRNA) therapeutic developed by Shanghai Rona Therapeutics for the treatment of Myotonic Dystrophy Type 1 (DM1). It is the lead candidate from the company's proprietary APOLLO platform, which is specifically engineered for the delivery of RNA therapeutics to extra-hepatic tissues, including skeletal and cardiac muscle. RN517 is designed to target and silence the Dystrophia Myotonica Protein Kinase (DMPK) gene, aiming to reduce the levels of toxic CUG-repeat expansion transcripts that cause RNA-mediated toxicity and spliceopathy in DM1 patients. By degrading these toxic mRNA species, RN517 seeks to reverse the underlying molecular pathology and alleviate muscle dysfunction. The program is currently in the preclinical stage of development.